INOVIO PHARMACEUTICALS INC (INO)
US45773H4092 - Common Stock
Which stocks are moving on Friday?
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Top movers in Friday's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
INOVIO Announces Pricing of $30 Million Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
These stocks are moving in today's after hours session
Stay updated with the stocks that are on the move in today's after-hours session.
INOVIO Announces Proposed Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
INOVIO Reports Inducement Grant Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
INO earnings call for the period ending September 30, 2024.
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an...
INOVIO to Present at Upcoming Scientific Conferences
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to...
Inovio Pharmaceuticals Enters Oversold Territory (INO)
INOVIO Reports Inducement Grants Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Present at Upcoming Scientific Conferences
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Present at Upcoming Scientific Conference
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Relative Strength Alert For Inovio Pharmaceuticals
Commit To Purchase Inovio Pharmaceuticals At $7, Earn 34% Annualized Using Options
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
INO earnings call for the period ending June 30, 2024.
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the second quarte...
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Commit To Buy Inovio Pharmaceuticals At $6, Earn 21.6% Annualized Using Options
INOVIO Reports Inducement Grant Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Reports Inducement Grant Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...